You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH)業績快報:2021年度實現營收40.14億元 同比增長151.71%

格隆匯2月25日丨君實生物(688180.SH)發佈2021年度業績快報,實現營業總收入40.14億元,同比增長151.71%。報吿期內,公司營業收入大幅提升,主要來源於技術許可收入的大幅增長特許權收入的新增以及特瑞普利單抗注射液(商品名:拓益®)國內市場商業化帶來的銷售收入。其中,技術許可收入及特許權收入的情況如下:

1、根據公司與 Eli Lilly and Company(“禮來製藥”)簽署的《研發合作和許可協議》,隨着合作的快速推進,埃特司韋單抗(JS016/LY-CoV016)對禮來製藥的海外授權已達成協議約定的全部里程碑事件。此外,公司與Coherus BioSciences, Inc.簽署了《獨佔許可與商業化協議》,雙方約定在美國和加拿大區域開展腫瘤免疫領域的深度合作。基於上述兩項合作,報吿期內公司技術許可收入大幅增長

2、基於海外疫情的發展,截至報吿期末,埃特司韋單抗及巴尼韋單抗(LY-CoV555)雙抗體療法已在超過15個國家和地區獲得緊急使用授權。隨着該雙抗體療法的商業化推進,報吿期內公司新增相關特許權收入

報吿期內,公司持續加大研發投入,通過自主研發以及合作開發/權益引入(License-in)等形式不斷豐富和拓展在研產品管線,持續探索藥物的聯合治療,快速推進現有臨牀項目的開展和儲備研發項目的開發,並加速推進多個具有源頭創新性(first-in-class)或差異化開發價值的產品管線。報吿期內,公司十餘項自研或合作開發項目的臨牀試驗申請獲得批准,特瑞普利單抗新增3項適應症獲得國家藥品監督管理局(“國家藥監局”)批准上市,2項新適應症上市申請獲得國家藥監局受理。截至公吿披露日,公司研發管線已涵蓋超過45在研產品覆蓋五大治療領域。其中,處於商業化階段的在研產品共2項(特瑞普利單抗以及埃特司韋單抗),處於新藥上市申請階段在研產品1(阿達木單抗),除上述產品外另有超過20項在研產品處於臨牀試驗階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account